Istituto Oncologico Veneto Irccs

This early-stage study aimed to find safe doses of a drug called regorafenib when added to standard treatment for a fast-growing brain tumor called glioblastoma. Researchers tested the drug combination in 21 adults who had recently been diagnosed. The main goal was to determine h…

This trial tested whether adding a year of avelumab, an immunotherapy drug, after standard surgery and chemotherapy could help keep cancer from returning in patients with high-risk triple-negative breast cancer. It involved 474 patients who had already completed their main cancer…

This study looked back at the medical records of over 1,000 patients to understand how doctors currently diagnose and treat two rare, high-risk types of abnormal breast cells (FLCIS and PLCIS). The goal was to gather real-world evidence on what treatments are used and how well th…